10th Apr 2014 08:02
LONDON (Alliance News) - Physiomics PLC said Thursday that it will be demonstrating a new validation of its Virtual Tumour Clinical Platform at a workshop in France, with a study that shows the platform can be used to make accurate predictions of clinical outcomes.
The Virtual Tumour Clinical platform is a technology that uses a mathematical model to predict the growth of tumours.
The study will demonstrated this using a phase II clinical trial of Docetaxel compared to a Docetaxel/Selumetinib treatment for metastatic melanoma, where the Virtual Tumour Clinical was able to accurately predict the change on tumour lesion diameter in both sides of the study.
The study was part of the company's three month collaboration with Mark Middleton of the Oxford University hospitals NHS trust and was supported by the UK government's Technology Strategy Board.
It will be presented by Hitesh Mistry at the Coordinating Action Systems Medicine Academic and Industry interaction workshop in Lyon, France on Thursday.
"Predicting Clinical outcomes for particular drug regimens is of significant interest to large pharmaceutical companies and could help them to increase their drug development success rates," said Chief Executive Mark Chadwick in a statement,
Shares in Physiomics were trading up 8.7% at 0.163 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Physiomics